Beyond the Flush: Reframing ALDH2 deficiency as a public health risk

During the late 1980s, a phenomenon known as “Alcohol Flushing Syndrome” began to capture attention when researchers from the Indiana University School of Medicine pinpointed a genetic variant, ALDH2*2, as the underlying cause of the physiological reaction commonly referred to as “alcohol flushing”. Research revealed that this variant disrupts the body’s ability to efficiently oxidize acetaldehyde, a breakdown product generated during the metabolism of alcohol [1]. In addition to its role in the flushing reaction, this deficiency has been linked with an increased risk for esophageal cancer [2], Alzheimer’s disease [3], and cardiovascular disease [4].

The point mutation in ALDH2*2, affecting 8% of the world population or, more specifically, 560 million people of East Asian descent [5], is the “most common single point mutation in humans” [6]. Yet, despite its prevalence, very few people in healthcare know about the aforementioned health risks. This lack of public and professional awareness has resulted in insufficient attention to the associated health risks among those who may be impacted.

Evidence from large-scale selection analyses shows ALDH2*2 prevalence grew rapidly in East Asia within the last approximately 2,000 to 3,000 years, indicating recent positive genetic selection rather than genetic drift [7–9]. Strong selection signals co-occur with alcohol dehydrogenase 1B (ADH1B), suggesting pressures related to alcohol metabolism and/or nutrition [10, 9], and the timing roughly overlaps with rice domestication, when fermented beverages and dietary shifts became common [11, 12, 9]. Several hypotheses may explain the advantage: (1) reduced alcohol consumption among carriers due to alcohol flushing may have lowered alcohol-related liver disease and cirrhosis; (2) protection has also been reported against infections such as tuberculosis [13, 9]; and (3) geographic correlations with hepatitis B raise the possibility of infection-related fitness benefits [14, 9]. Population biobank data also suggest protection from certain cardiovascular outcomes (e.g., atrial flutter, ischemic stroke), which could have modestly favored carriers [15, 9]. Although the exact dominant driver remains unresolved, it is probably multifactorial.

Alcohol consumption, in any quantity, poses significant global health burden; any modest benefits at low intake are eclipsed by elevated risks, including cancer [16, 17]. Among individuals who consume alcohol, the ALDH2*2 variant dramatically heightens the risk of esophageal cancer. With light drinking, the risk of esophageal cancer increases by 26%, but it increases by 395% with heavy drinking [18]. Furthermore, a recent report identified that alcohol use contributed to 4% of all cancers annually worldwide and, importantly, East Asian populations were observed to bear the highest burden of alcohol-associated cancer(s) compared to all other racial and/or ethnic groups [19, 20]. Acetaldehyde’s carcinogenic properties, largely via DNA adduct formation, are well established by both epidemiological and mechanistic studies, reinforcing that ALDH2 deficiency significantly amplifies cancer risk – particularly in the upper digestive tract [21]. By contrast, ALDH2*2 carriers who abstain from alcohol consumption are not reported to exhibit these alcohol-mediated increases in esophageal cancer risk. Clinically, the alcohol flushing response serves as a noninvasive biomarker for ALDH2 deficiency, allowing healthcare providers to screen high-risk patients and prompt early cancer surveillance and counseling [2].

Emerging evidence links the ALDH2*2 variant to increased risk of Alzheimer’s disease, particularly in East Asian populations. A case-control study showed that ALDH2 deficiency correlates with greater susceptibility to late-onset Alzheimer’s disease, with ALDH2 knockout mice developing memory deficits, brain atrophy, lipid peroxidation, and hallmark Alzheimer’s disease pathologies such as amyloid-β accumulation and tau activation — patterns that mirror human disease and are more pronounced than in wild-type mice [22–24]. More recent mechanistic work indicates that in ALDH2*2 carriers, chronic alcohol exposure exacerbates oxidative stress, aldehydic load, mitochondrial dysfunction, and amyloid-β accumulation, effects that are dampened by Alda-1, a small molecule activator of ALDH2 activity [3]. These neurodegenerative exacerbations are alcohol-mediated; abstinent ALDH2*2 carriers are not reported to exhibit alcohol-mediated increases, and even moderate alcohol consumption in the general population is associated with increased brain atrophy and amyloid plaque burden [25]. While research in humans remains limited, the strong preclinical and in vitro data highlight the neuroprotective role of ALDH2 and underscore its deficiency as a potential modifiable risk factor for Alzheimer’s disease, warranting further investigation in large-scale epidemiological studies.

Additionally, there are important considerations for the management of heart disease and stroke specific to East Asians with the ALDH2*2 variant. A recent study highlighted the significance of ALDH2 in mediating ischemic damage to the heart and brain through reactive aldehyde metabolism [26]. The study recommends that, when considering cardiovascular health, physicians should consider the presence of the ALDH2*2 variant in East Asians. This variant not only severely limits reactive aldehyde metabolism, but also affects the metabolism of certain drugs, such as nitroglycerin, and thus screening for this variant could prove beneficial.

Individuals with ALDH2*2 variant face an elevated risk of myocardial infarction [27] and coronary artery disease [28], conditions that account for a staggering 19% of Asian American deaths in the United States. ALDH2*2 is also associated with a higher risk of hypertension and studies have shown that East Asian Americans have high rates of hypertension compared to non-Hispanic Whites, despite having lower rates of obesity [29–31]. ALDH2 is an important mediator in reducing cellular damage from a stroke, and individuals homozygous for the ALDH2*2 variant have an 86% increased risk of ischemic stroke compared to individuals with homozygous for the reference variant, ALDH2*1 [32–34]. Although some studies link light to moderate alcohol consumption with lower rates of coronary events [35–41], sustained heavy and/or binge alcohol consumption is cardiotoxic causing mitochondrial injury, myocyte loss, impaired contractility, altered heart-rate variability, arrhythmias, and structural remodeling [42–44, 36, 45, 46, 39, 47, 40]; habitual high intake (>90 g ethanol/day for >5 years) is strongly associated with dilated “alcoholic” cardiomyopathy [48, 46, 40], a major driver of alcohol-related cardiac morbidity and mortality [49, 43, 50, 46, 51, 52, 40]. Importantly, these risks are seen in broad East Asian populations, and not exclusively in those who drink alcohol. Consistent with this, abstinent ALDH2*2 carriers are not reported in the existing literature to exhibit alcohol-mediated increases in cardiovascular and/or cerebrovascular risk. Given the preventive health measures (i.e., improved blood pressure control, healthy diet, physical activity, decreased alcohol intake and smoking) that are available to improve cardiovascular health, knowledge of genotype and improved health management should be of high priority.

While screening for ALDH2*2 does not displace universal prevention; it can help operationalize it for those at greatest near-term risk. ALDH2*2 carriers who consume alcohol start from a higher baseline risk and, as such, the absolute benefit of abstinence or cessation is larger and genotype disclosure improves risk salience and behavior change. General lifestyle changes (e.g., exercise) are not reported in the literature to have a stronger causal effect in ALDH2*2 carriers. Instead, the value is in both prioritization and adherence using a personalized narrative to drive uptake of proven public health interventions. In fact, screening and subsequent genotype-specific genetic counseling have demonstrated stronger behavior change (i.e., frequency and the quantity of alcohol consumption) than traditional alcohol education [53] or no education at all [54]. Notably, participants with ALDH2*1/*1 genotypes reported increased risk perception and intention to reduce drinking behavior with no significant change in 30-day drinking quantity, typical weekend drinks, or drinking frequency versus control. Participants with ALDH2*1/*2 genotypes reported increased risk perception with no significant intention to reduce drinking behavior but demonstrated significant decrease in 30-day drinking quantity, typical weekend drinks, or drinking frequency versus control. Participants with ALDH2*2/*2 genotypes did not report significant intervention effects on drinking or secondary outcomes, likely because individuals with *2/*2 genotypes already consume alcohol minimally at baseline [54].Together, these findings show that genotype-informed genetic counseling drives meaningful reductions in alcohol consumption and should be embedded as standard of care whenever ALDH2 status is disclosed. We believe that while screening and having genotype-specific information is important, it is more essential that communities most affected are aware of the potential health risks and have the autonomy to choose whether they would like to engage in screening.

In clinical settings in the United States, there is little to no testing of the ALDH2*2 variant and thus, no discussion of appropriate follow up care for those carrying this variant. Direct-to-consumer (DTC) genetic testing companies that offer testing for ALDH2, like 23andMe, market this genetic screening as a way to understand one’s risk of alcohol intolerance – a “wellness” rather than disease trait. While some DTC genetic testing companies acknowledge that these variants are associated with an increased risk of esophageal cancer(s) and even recommend periodic medical examinations, the emphasis is placed on alcohol flushing and alcohol intolerance rather than integration of findings into clinical care. As a result, individuals may receive information about increased health risks (e.g., cancer) but still remain unaware of the broader medical management considerations related to carrying this variant – a key limitation. Some DTC genetic testing companies may choose to omit ALDH*2 associated health risks altogether to stay within general “wellness” claims and avoid medical claims that would trigger FDA scrutiny and require stronger evidence of clinical utility. The DTC genetic testing space shows wide variation in reporting practices and ongoing concerns about consumer safety, privacy, and third-party reinterpretation outside traditional oversight. In such areas without standardized results reporting and/or management pathways, firms may purposefully keep ALDH2 in a wellness frame rather than make disease-risk statements [55].

While flushing questionnaires and ethanol patch tests are available to screen for the presence of this variant, the sensitivity and specificity of these methods prove to be suboptimal [56]. Flushing questionnaires for non-drinkers have the potential to return false negative results for individuals with the ALDH2*2 variant who abstain, or limit alcohol consumption. According to a 2022 survey, 36% of Asian Americans have never used alcohol in their lifetime – the largest proportion of all racial and ethnic groups [57]. These individuals may be unaware of their genetic predisposition because they have never flushed, yet they still carry multifaceted cardiovascular risks associated with this variant. Other studies have found that the discomfort of alcohol flushing is a protective factor and people with the ALDH2*2 variant are less likely to drink than people who do not flush [58]. Thus, genetic testing is the most accurate method for determining whether someone has the ALDH2*2 variant. However, genetic testing for ALDH2 has not been implemented into clinical practice and the healthcare of people who flush.

The 2015 Precision Medicine Initiative had the goal of improving how we prevent and treat disease for everyone, moving beyond the concept of the “average patient” [59]. With this initiative, it was also stressed that there is an unmet need to improve the quality of healthcare for Asian Americans. According to the last census data, Asian Americans are the fastest growing racial/ethnic group in the United States, and yet, due to stereotypes, systemic racism, and misperceptions, there has been little to no focus on Asian Americans in precision public health efforts for the past decade.

In addition to personalized health management, employing a precision public health medicine approach to detect individuals with an ALDH2*2 variant could potentially pave the way for targeted treatments. A few years ago, Matsumura et al. (2019, 2020) conducted studies outlining the successful use of gene therapy to correct the deficiency state of ALDH2 in animal models [60, 61]. The authors concluded that, if this strategy proves effective in humans, it could not only mitigate the risks associated with ALDH2 deficiency by reducing alcohol-mediated mucosal injury, but also alleviate the discomfort of alcohol-induced alcohol flushing for individuals [60–62]. A potential drawback to this treatment is that by alleviating symptoms, it would enable affected individuals to consume larger quantities of alcohol, removing the protective behaviors associated with ALDH2 deficiency. Thus, although treating ALDH2 deficiency with gene therapy raises ethical concerns such as risk compensation,, there exists the potential to reduce the elevated risks of esophageal cancer and Alzheimer’s disease, and therefore warrants consideration as a possible treatment option.

The identification of ALDH2*2 represents an ideal opportunity to implement the goals of precision public health – delivering tailored treatments precisely when they are needed. Asian Americans have been held up as the “model minority” but this stereotype and other misperceptions have contributed to systemic racism in biomedical research and a lack of focus on precision medicine efforts directed towards this population. As a medical community, it is imperative that we determine how to utilize the information currently available about ALDH2*2 and integrate it into existing medical practices to mitigate the undeniable health risks associated with this variant. Awareness of the essential role of ALDH2 in health, beyond its effects on alcohol metabolism, will undoubtedly improve healthcare for the growing East-Asian population in the United States and globally.

We suggest the following key steps to address a public health genomics approach for ALDH2:

1. Engage the community – Establish direct, sustained engagement of community members most affected by the ALDH2*2 variant. In our preliminary work, East Asian Americans have little to no awareness of the health risks associated with alcohol flushing and feel strongly that this knowledge should be disseminated in healthcare settings so that patients can choose whether or not to be screened. This type of collaboration between community members, researchers, and healthcare systems is necessary to build trust, ensure cultural relevance, promote awareness, and integrate of genetic testing [63].

2. Expand research on treatments and prevention – Invest in studies that explore therapeutic interventions (e.g., pharmacologic activators of ALDH2 protein, lifestyle modifications, and potential gene therapy approaches) and preventive strategies aimed at reducing alcohol-associated cancers, cardiovascular, and neurodegenerative disease risks in individuals with ALDH2 deficiency.

3. Develop clinical guidelines – National and international medical organizations should incorporate ALDH2 genotyping into evidence-based practice guidelines, providing clinicians with recommendations for screening, risk stratification, counseling, and management of patients carrying the ALDH2*2 variant.

4. Prioritize equity-focused implementation – Ensure that ALDH2 genetic screening is accessible and delivered through a health equity lens. Screening programs must avoid exacerbating existing disparities and should include culturally tailored education, community outreach, and inclusive policies that promote equitable access to testing and follow-up healthcare.

Conclusion: Reframing ALDH2*2 as a precision public health issue

The ALDH2*2 variant is not benign. As the population of East Asian descent grows in the U.S., integrating genotype-informed strategies into clinical care is essential. A precision public health framework, centered on awareness, prevention, surveillance, and translational research, can improve outcomes for individuals with ALDH2*2. Prioritizing this framework can also shift public perspectives of “alcohol flushing” from a funny phenomenon to serious and legitimate health condition.